The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

In a systematic review of 14 studies, researchers evaluated the association between body mass index and clinical outcomes in patients with HR+ HER2- metastatic breast cancer who were treated with CDK4/6 inhibitors. Based on the heterogeneous results, they concluded that body mass index is an insufficient surrogate for body composition and does not consistently predict CDK4/6 inhibitor efficacy.